This update expands the prior scientific statement on the relevance of genetics and genomics for the prevention and treatment of CVDs. 2 In the earlier report, we focused on the current status of the field, which consisted of predominantly family-based linkage studies and single-gene or mendelian mutations of relatively large phenotypic effect sizes. The past several years have seen many advances in genetics technologies that have allowed a new generation of genetic association discoveries and an explosion of reports in the literature of these new associations. Approaches such as genome-wide association studies (GWASs) and whole-genome sequencing have led to the discovery of novel genomic determinants of CVDs, and we focus on these findings. Unlike candidate gene association studies, hypothesis-generating GWASs and whole-genome sequencing studies have the potential to identify genes with previously unknown (and even unsuspected) roles in CVD. These findings are in various stages of translation to both the clinical setting and basic functional research aimed at uncovering new mechanisms operative in CVDs.
The basic methodology for GWASs is to analyze singlenucleotide polymorphisms (SNPs) across the genome in association with dichotomous (case-control) or continuous traits. SNPs are analyzed by genotyping arrays capable of interrogating millions of SNPs directly and predicting millions more genotypes via imputation. Multiple test corrections and replication of findings in independent samples are done to demonstrate that statistical findings are robust. The remarkable discoveries from GWASs have brought enormous progress to identifying and understanding a portion of the cause of complex CVD. The basis for the remaining portion of genomic cause is uncertain but has been hypothesized to reside in less common, rare, or very rare sequence variants. [3] [4] [5] Further information on GWAS methodology can be found in several excellent reviews. [6] [7] [8] In addition to genomic technologies reviewed in the initial statement 2 and GWASs, methods such as massively parallel next-generation sequencing 9, 10 are greatly extending our knowledge of human genetic variation and genetic markers of CVD and related traits. The exome, defined as the ≈1% to 2% of the coding portion of the human genome, encompasses ≈19 000 genes. Exome or genome sequencing provides a novel and powerful research strategy for those conditions driven by uncommon or rare variants. 11 In this context, uncommon usually means allele frequencies of 0.5% to 5%; rare, <0.5%; and very rare, <0.1%. "Private" is applied to variants not previously reported, which depends on the number of other DNA sequences available for comparison at that locus. Sponsored by the National Heart, Lung, and Blood Institute, the Exome Sequencing Project (ESP), 12 undertaken in 2009, has now made available the exome sequences from >6500 individuals with cardiovascular, lung, or blood phenotypes (http://evs.gs.washington.edu/EVS/), greatly enhancing the power of determining how rare a variant may be. A recent ESP report of the initial 2440 exome sequences from European (n=1351) or African (n=1088) ancestry provided a remarkable snapshot of genetic variation. 13 Most variants identified were rare and previously undetected. Of the >500 000 single-nucleotide variants identified, 86% had an allele frequency <0.5%, and 82% were previously unknown; of the average of 13 595 single-nucleotide variants observed in each individual, 2.3% were predicted to affect the protein function in ≈313 genes. 13 Large-scale experiments in population samples are currently underway to test the hypothesis that rare variants, which are not polled by GWAS assays or imputation methods, may play a larger role in complex disease phenotypes than previously thought.
In this update, we review the advances and current state of knowledge in the key CVD areas previously discussed, including coronary artery disease (CAD), stroke, hypertension, and hypercholesterolemia. 2 Additionally, we review the areas of diabetes mellitus, inflammation, and pharmacogenetics. In the discussion of common variant associations, we highlight landmark studies and their findings. A comprehensive listing of associations may be found through resources such as the GWAS catalog.
14 This update also presents new research findings for mendelian diseases and the clinical approach to these disorders, focusing on cardiomyopathies, inherited arrhythmias, aortic aneurysms, and congenital heart defects. Policy recommendations are addressed in a separate American Heart Association statement. 15 We discuss the functional translation of genetic findings for CVDs and stroke, as well as counseling and clinical translation considerations. We conclude with a set of recommendations identifying future directions and the education that will be required of clinicians, researchers, the general public, and our patients for maximal effect for research and translation of these findings to the clinical setting.
More recently, these 2 large consortia joined forces to form the CARDIoGRAMplusC4D consortium and executed a largescale replication of the top findings from CARDIoGRAM using the Illumina Metabochip, which assays ≈200 000 SNP markers in genes of interest for metabolic and CVD traits. 29, 30 Metabochip data in 34 independent sample collections of European or South Asian descent comprising 41 513 cases and 65 919 controls were combined with existing CARDIoGRAM GWASs to uncover an additional 15 loci, bringing the total number of GWAS susceptibility loci for CAD to 46 . 30 A further 104 independent variants strongly associated with CAD at a 5% false discovery rate and, together with the 46 loci reaching genome-wide variants, explain ≈11% of the additive heritability of CAD. Together, CARDIoGRAM and C4D 20, 23, 30 evaluated >200 000 individuals and have identified and replicated >30 novel loci for CAD susceptibility (Table 1) .
These GWAS investigations were comprehensive in that they also assessed gene expression (for genes in the implicated loci) in tissues using human cell lines, evaluated genome-wide maps of allelic expression imbalance, compared "hits" for CAD with those for common CVD risk factors, and performed complex network analyses. 20, 23, 30 The functional impact of the identified loci was interpreted on the basis of the association of CAD-associated alleles with traditional CAD risk factors, through which the genetic risk for CAD is likely imparted, 35 Interestingly, in these analyses adjusted only for age and sex, the lead SNP in 12 of the 46 validated CAD susceptibility loci was found to be significantly associated with a lipid trait in the Global Lipids Genetics Consortium data set (predominantly low-density lipoprotein [LDL] and triglycerides) and 5 with blood pressure (BP) in the International Consortium of Blood Pressure data set, underscoring the strong causal influence of these risk factors on CAD risk. 30 Network analysis also indicated a causal association between pathways of inflammation and CAD. 30 The functional impact of these loci has also been pursued through the use of molecular methods in transgenic mouse models for the 9p21 association with CAD. 35 Finally, a recent modest-sized GWAS of ≈1500 Han Chinese subjects with CAD and 5019 control subjects followed by a large-scale replication of top findings in 15 460 cases and 11 472 controls replicated 4 loci uncovered in Europeans and implicated 4 novel loci. 31 Two of the novel loci have also been implicated in hypertension in Europeans. 31 This GWAS was unable to replicate an association between rs6903956 at 6p24.1 (c6orf105) and CAD uncovered by a previous smaller GWAS in a Chinese Han population despite adequate power to detect it. 31, 32 These studies highlight several key points. First, many CAD loci have consistent effects across studies of various ethnicity and for both men and women, 20, 31 although data on African Americans and other non-European ancestry ethnic groups remain relatively limited. Second, associations were generally stronger for early-onset CAD compared with lateronset CAD, suggesting that selecting individuals with premature CAD phenotypes enriches for genetic factors and may yield additional valuable insights in future studies. 23 Third, associations were stronger for hard end points such as MI and angiographically defined CAD, again emphasizing the importance of careful phenotyping for GWASs. 23 Fourth, as noted in other GWASs, the effect sizes in these studies typically were modest (often with odds ratios <1.2) with a 5% to 20% excess risk associated with select loci (Table 1) . Consequently, these genetic loci explain only a small proportion of the heritability of CAD. Presumably, additional common variants with very modest effects, gene-environment and gene-gene interactions, rare genetic variants (GWASs focused on SNPs with a minor allele frequency typically >5%), structural variation, epigenetic modifications, microRNA, altered splicing, and posttranslational modification of proteins also contribute to the residual unexplained heritability. 3, 23, 36 These observations underscore the importance of a multifaceted investigation strategy harnessing the tools of systems biology to better elucidate the genetic basis of CAD. Fifth, a minority of the loci implicated in CAD were associated with traditional CVD risk factors, including lipids and BP, whereas others were associated with myriad other common diseases and traits, including hematologic and biochemical traits and intracranial aneurysm, thereby pointing to the pleiotropic effects of these loci. 15, 20, 23 Sixth, whereas the list of loci implicated in CAD is long, the exact causal variants and mechanisms by which these candidate variants and candidate genes mediate their effects remain to be elucidated for most loci. Such additional work involves careful experiments like those accomplished for the SORT1 locus, for which there is some evidence for causal associations with LDL cholesterol (LDL-C) and CAD. 37 Finally, the contribution of these newer loci to risk prediction and their clinical utility remain to be clearly demonstrated in future studies, although improvement in this respect has been noted in some cohorts.
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Ischemic Stroke
Stroke is a heterogeneous and complex disease composed of 3 main types: ischemic stroke, intracerebral hemorrhage, and subarachnoid hemorrhage. Within the phenotype of ischemic stroke, various subtypes appear to differ in degree of heritability. 42 Here, we focus on ischemic stroke and its subtypes. GWASs have provided the strongest evidence for loci associated with the common form of ischemic stroke (Table 2) . To date, all such loci have had 2 characteristics. First, most of the loci have been discovered in other mechanistically related conditions such as atrial fibrillation, CAD, and coagulation, with subsequent confirmation of associations with ischemic stroke. This is not unexpected, given the pathogenic associations between stroke and these other traits and because the GWASs of these other conditions have far greater sample sizes and statistical power compared with the GWASs of ischemic stroke. Second, the associations are specific to subtypes of ischemic stroke. For example, a locus on chromosome 4q25 adjacent to the transcription factor PITX2 (codes for pituitary homeobox 2), found to be associated with atrial fibrillation, was subsequently found to be associated with cardioembolic stroke. 52 Additionally, a locus on chromosome 16q22 involving ZFHX3 (the zinc finger homeobox protein 3) has been associated with both atrial fibrillation and cardioembolic stroke. 53 Similarly, a pooled analysis demonstrated that 6 SNPs in the chromosome 9p21 locus, first identified through a heart disease GWAS, 26 are associated with atherosclerotic stroke independently of demographic variables, CAD, MI, and other vascular risk factors. 54 The 9p21 locus seems to affect stroke risk independently of the risk of MI. Genetic variants identified through GWASs of coagulation/fibrin phenotypes were subsequently examined for association with ischemic stroke. The rs505922 in the ABO gene was found to have a replicated association with large-vessel and cardioembolic stroke. 28, 55 GWASs have yet to identify a locus that imparts risk by modifying tissue sensitivity to ischemic injury. A genetic variant that imparts sensitivity of the brain parenchyma to focal ischemia might be expected to have an association across ischemic stroke subtypes while lacking an association with conventional atherosclerotic risk factors for stroke such as atrial fibrillation and hypertension (parenchymal hypothesis).
More recently, GWASs of ischemic stroke have identified novel loci that were not previously identified through GWASs of other CVDs. Variation in HDAC9 (codes for histone deacetylase 9) has been associated with large-vessel atherosclerotic stroke. 51 In addition to confirming ischemic stroke loci initially identified in nonstroke GWASs (PITX2, ZFHX3, and the 9p21 locus), a meta-analysis that involved 12 389 cases of ischemic stroke confirmed the HDAC9 locus.
56 HDAC9 variants seem to relate to the predisposition to atherosclerosis. 57 As with HDAC9, a novel locus associated with large-vessel ischemic stroke was first discovered in a stroke GWAS. 58 Mitochondrial DNA has been shown to harbor variants associated with stroke risk. Mitochondrial DNA is another important part of the human genome, separate from nuclear chromosomal DNA. Mitochondrial DNA is inherited directly from mother to child because of the presence of mitochondria in the oocyte, which gives rise to all mitochondria in the developing tissues. Because of the association of mitochondrial DNA variants with the MELAS (mitochondrial encephalopathy, lactic acidosis, and stroke-like episodes) syndrome, a monogenic cause of ischemic stroke, 59 the role of mitochondrial variants in the common form of stroke has been investigated. A mitochondrial genetic risk profiling study that included all common variants has also shown that common variants are associated with ischemic stroke and with white matter hyperintensity volume. 60 Consistent with the GWASs for CAD and MI, the effect sizes of the associated mitochondrial variants for stroke are modest, impeding our ability to discern which particular loci are most useful for profiling in the clinical setting. 60 Family studies continue to provide new insights into monogenetic causes of cerebrovascular disease and novel disease mechanisms and pathways. Variants in ACTA2, the vascular smooth muscle cell-specific isoform of α-actin, smooth muscle myosin gene (MYH11), [61] [62] [63] and multiple transforming growth factor-β signaling genes, including TGFBR1, [64] [65] [66] [67] TGFBR2, [68] [69] [70] TGFB2, 71, 72 and SMAD3, 73, 74 have been shown to cause familial aortic aneurysms and dissection and to have cerebrovascular manifestations. [64] [65] [66] [67] [68] [69] [70] 75 More recently and similar to the pleiotropic effects of the 9p21 locus, some of the same variants associated with premature CAD are also associated with premature ischemic stroke, including moyamoya disease, which is also associated with other variants such as RNF213. 76, 77 Laboratory studies demonstrate that these mutations are associated with increased proliferation of smooth muscle cells. 78 Although these mutations were found not to be associated with sporadic premature CAD and stroke, these findings suggest a new pathway to target in future genetic research.
Global gene expression profiling has recently been studied as a potential tool for distinguishing ischemic stroke from other conditions 79 and for identifying the underlying mechanism of ischemic stroke. 80 Gene expression profiles from RNA isolated from sequential early blood samples were able to distinguish large-artery atherosclerotic stroke from cardioembolic stroke and to distinguish cardioembolic stroke related to atrial fibrillation from non-atrial fibrillation cardioembolic There has also been strong interest in targeting subclinical vascular disease phenotypes as additional traits for GWAS investigations. The Cohorts for Heart and Aging Research in Genomic Epidemiology Consortium 82 conducted a metaanalysis of GWASs for coronary artery calcium measured by thoracic computed tomography in 9961 men and women from 5 community-based cohorts and replicated the most promising candidates in 3 independent cohorts (n=6032). 83 Several of the loci significantly associated with coronary artery calcium had previously been shown to be associated with MI. These included loci in the 9p21 region (CDKN2B) and SNPs associated with PHACTR1 and COL4A2. Interestingly, other established MI loci showed considerable statistical evidence (although they failed to meet GWAS significance) for association with subclinical coronary disease, including the SORT1/ CELSR2/PSRC1 locus, MRAS, CXCL12, the COL4A1/ COL4A2 locus, and ADAMST7. The convergence of GWAS evidence for both clinical events and anatomic coronary disease provides even more compelling validation of many of the genetic variants and strongly suggests that their apparent associations with MI are likely attributable to influences on the pathogenesis of atherosclerosis rather than other mechanisms that contribute to the development of acute coronary syndromes.
In a much larger GWAS meta-analysis involving 31 211 subjects in discovery and 11 273 subjects in replication cohorts, the Cohorts for Heart and Aging Research in Genomic Epidemiology consortium also sought genetic variants associated with common carotid intima-media thickness and carotid plaque. 84 However, despite the larger samples sizes, only 2 of the 8 loci with genome-wide or nearly genome-wide SNPs associated with intima-media thickness or plaque were linked to CAD in the CARDIoGRAM consortium (LDLR and EDNRA), supporting the concept that these carotid phenotypes likely share some pathogenic mechanisms that are distinct from those contributing to CAD.
In the aggregate, these GWAS meta-analyses targeting subclinical vascular disease traits provide important additional validation for a number of loci related to the pathogenesis of atherosclerosis. Although some of these loci have biologically plausible links to CVD risk factors or known cellular mechanisms involved with atherogenesis, others implicate genes with no currently recognized link to vascular disease. These novel discoveries are now motivating further hypothesis-driven research that may ultimately lead to fundamentally important new discoveries concerning genetic determinants of CVD.
Hypertension
BP genetics have been largely illuminated by gene identification studies in mendelian hypertension and hypotension syndromes with specific electrolyte and other biochemical abnormalities. 85 These studies show that functional defects in renal sodium reabsorption or activation of mineralocorticoid activity in the distal nephrons of the kidney and their consequent effects on the renin-angiotensin-aldosterone system lead to biochemical and physiological imbalance in hypertension syndromes and confirm the "renal hypothesis" of Arthur Guyton. 86 However, these mendelian mutations are rare, have negligible population-attributable risk, and, even collectively, constitute a small fraction of secondary hypertension cases. Recent studies have attempted to assess the role of rare variants in renal salt-handling genes in essential hypertension and interindividual BP variability. However, once again, these "mendelian" genes make very small contributions to hypertension risk in the population. 87 In 2004, Wilson and colleagues 88 published data from an unusual white kindred, segregating hypomagnesemia, hypertension, and hypercholesterolemia, which they traced to a mitochondrial isoleucine tRNA mutation. Although the mechanistic basis of this genotype-phenotype connection is not understood, other mutations in this same gene have been identified in a large Chinese kindred. 89 Thus, mitochondrial dysfunction, as a consequence of aging, may be a general mechanism for essential hypertension; however, this remains an unproven but exciting hypothesis. The association of mitochondrial variants with hypertension in the population, as has been done for stroke, has yet to be explored. There are physiological reasons to suspect that many other genes affecting functions of the adrenal gland, brain, blood, or vasculature play critical roles in hypertension. BP is a classic heritable quantitative trait, with 30% to 60% heritability in humans and many different genes contributing to this variation. 90 The difficulty in making firm conclusions about the role of specific genes in hypertension is that the constituent studies are very heterogeneous with respect to the trait measured (BP versus hypertension versus postural hypertension, etc), measurement technique, treatment, comorbidities, ascertainment, sample size, and genetic methodology. Few findings, except for the roles of genetic variation in the renin-angiotensin-aldosterone system pathway in BP and hypertension, have consistently been replicated because of study differences and low statistical power. [90] [91] [92] However, in the past 3 years, carefully designed GWASs based on phenotype harmonization and high statistical power have convincingly identified numerous loci involved in BP control and hypertension.
Two large GWASs of individuals of European ancestry were published in 2009 and reported 13 loci for systolic BP, diastolic BP, and hypertension. 92, 93 The 2 consortia that reported these results then combined cohort-level association results into a single consortium effort, the International Consortium of Blood Pressure, for a single combined "mega-meta-analysis," comprising >79 000 samples for the discovery phase and >200 000 individuals from diverse ancestral populations in the discovery and replication phases. 94 In total, 29 loci were found to be associated with systolic BP, diastolic BP, and hypertension (Table 3) ; however, in total, these loci account for <1% of the trait variance (or <3% of the genetic variance), suggesting that the vast majority of the genetic variance of BP traits in the general population has yet to be accounted for. The 29 loci taken together were, unsurprisingly, significantly by guest on http://circ.ahajournals.org/ Downloaded from associated with hypertension, left ventricular wall thickness, stroke, and CAD; however, they were not associated with kidney disease or kidney function. This suggests the hypothesis that in the majority of individuals renal susceptibility is not inherent but develops consequentially from prolonged high BP. The International Consortium of Blood Pressure conducted an analysis of age-adjusted mean arterial pressure and pulse pressure and reported an additional 6 loci. 100 The novel pulse pressure loci were viewed as markers for genes affecting arterial stiffness and elasticity of the arterial wall, despite adjustment for age ( Table 3) .
As with most GWAS efforts to date, studies of BP and hypertension have been completed in European ancestry populations and have been highly successful in identifying new loci and genes associated with this complex trait. In part, this success is owed to the large sample sizes available and consequent high statistical power. GWASs in non-European ancestry individuals have also been performed, but fewer loci have been discovered and even fewer have been replicated, likely because of their much smaller sample sizes. 98, 102, 108, 109 This difference may result from low statistical power and not genetic heterogeneity because the 29 International Consortium of Blood Pressure loci discovered in European individuals have been demonstrated to jointly have highly significant effects in African, East Asian, and South Asian individuals (Table 3) . 94 Genomic studies of BP and hypertension have also been extended to other useful surrogates. In a recent study, Johnson and colleagues 99 examined polymorphisms in 30 genes that are hypertension drug targets. Specifically, they showed significant evidence of the role of an adrenergic receptor (ADRB1) and AGT on BP, demonstrating the importance of considering pharmacogenetic interactions.
The recent genetic studies have highlighted 3 major features of BP control and hypertension. First, although the roles of specific genes at the loci identified have not been definitively proven, the existing loci do not overlap any of the mendelian hypertension and hypotension syndrome genes or the renin-angiotensin-aldosterone system, except for the angiotensinogen (AGT) and congenital adrenal hyperplasia (CYP17A1) loci. Second, the candidate genes strongly implicate the roles of natriuretic factors (their precursors, NPPA and NPPB; the natriuretic peptide clearance factor NPR3; subunits of the soluble guanylate cyclase, GUCY1A3 and GUCY1A3; and adrenomedullin [ADM] and metal ion transporters [the iron transporter HFE and the zinc transporter SLC39A8]), together with novel renal genes (electroneutral sodium bicarbonate cotransporter SLC4A7 and phospholipase C-epsilon-1 isoform PLCE1). These findings are consistent with some earlier studies that have demonstrated a role for NPPA, NPPB, and endothelial nitric oxide synthase. 97, 110 Third, although the GWAS loci were detected through normotensive individuals, they have very strong and significant effects on CVD but not renal disease, supporting the hypothesis that essential hypertension in the population is primarily a CVD with primary defects in arterial function. The renal defects may be downstream and a consequence of these vasodilatory defects. 111 Because at least half of the variation in serum cholesterol and other lipids can be explained by genetic variation, 112, 113 unraveling the genetic pathogenesis of hypercholesterolemia and other lipid abnormalities could reap significant public health benefits by providing a knowledge base for the development of novel treatments or screening tests to determine who would most benefit from lifestyle modification or treatment for dyslipidemias. Important strides to this end have, in fact, already been made.
Mendelian forms of hypercholesterolemia have been thoroughly studied; these studies have proven critical in advancing our understanding of cholesterol metabolism and developing effective pharmacological therapies. 114 For example, familial hypercholesterolemia (FH) is the most common and potentially severe mendelian form of hypercholesterolemia. Caused by mutations in LDLR (≈700 are known), 115 FH causes elevated serum LDL-C concentrations. In FH homozygotes, LDL-C levels are generally unresponsive to dietary and pharmacological intervention; patients often develop clinically significant CVD before 30 years of age. 116 FH heterozygotes have elevated LDL-C, albeit lower than homozygotes, and generally are more influenced by environment and responsive to drug treatment.
A condition known as familial defective apolipoprotein B100 presents in a manner virtually indistinguishable from heterozygous FH. 117, 118 Apolipoprotein B100 is the major apolipoprotein present in LDL-C. Familial defective apolipoprotein B100 is caused by a mutation in APOB that influences the LDL receptor binding domain of apolipoprotein B100, ultimately resulting in decreased cellular uptake and processing of LDL-C. Familial defective apolipoprotein B100 is characterized by serum LDL-C concentrations that are 2.6 mmol/L (100 mg/dL) higher than LDL-C in individuals without mutations in APOB. Like those with FH, patients with familial defective apolipoprotein B100 respond favorably to drug treatment.
Other forms of monogenic hypercholesterolemia have been described. An autosomal-dominant form of hypercholesterolemia caused by a mutation of the proprotein convertase subtilisin/kexin type 9 gene (PCSK9) leads to a clinical presentation similar to that of heterozygous FH. [119] [120] [121] Although little is known about this form, recent research suggests that PCSK9 mutations affect LDL receptor protein expression and that at least 1 mutation (Ser127Arg) of PCSK9 is related to an overproduction of apolipoprotein B100. 119, [122] [123] [124] [125] Recessive forms of hypercholesterolemia such as autosomal-recessive hypercholesterolemia 126 (a mutation of the autosomal-recessive hypercholesterolemia protein gene ARH) and cholesterol 7α-hydroxylase deficiency hypercholesterolemia (a mutation of the cytochrome P450, subfamily VIIA, polypeptide 1 gene CYP7A1) are also reported. 127 More than 25 GWASs have sought to discover novel loci influencing lipid phenotypes. These include studies investigating the main effects of genotype on primary lipid phenotypes (plasma total cholesterol, high-density lipoprotein cholesterol, LDL-C, and triglyceride concentrations) and studies designed to identify variants that modify the relationship between known epidemiological risk factors (eg, alcohol consumption, adiposity) and lipid levels. Earlier GWASs were modestly powered with a few thousand participants in the discovery and replication stages 128 ; more recent meta-analyses have synthesized findings from multiple studies with total sample sizes in excess of 100 000. 129 The majority of lipid GWASs have been in cohorts of individuals of European ancestry, frequently ascertained on diabetes mellitus, obesity, metabolic syndrome, or other cardiovascular risk factors. East Indian and Asian populations have also been studied. 130, 131 Although the hope of GWASs is to identify novel common variants that may explain interindividual variation in potentially pathogenic traits, many lipid GWASs have reported highly significant associations (P<10 −20 ) between genes previously known or suspected to influence lipid metabolism. However, GWASs have also successfully identified genes without previously documented associations with lipid traits. 135, 136 ; NCAN
135
GWAS indicates genome-wide association study; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; TC, total cholesterol; and TG, triglycerides.
*Standards used by authors to specify "novel" genes varied from study to study, which, along with timing of publication, accounts for some genetic associations being judged novel in multiple studies.
†Genes are provided for those genes near or within the locus of the primary association signal. [150] [151] [152] and functional impact on lipid metabolism, demonstrating pleiotropy across these traits. 153 Other associations first observed in GWASs have prompted functional follow-up studies (eg, GALNT2, 154 
MYLIP
155
) and studies of gene associations with cardiovascular outcomes (eg, CELSR2-PSRC1-SORT1, NCAN-CILP2 associations with coronary heart disease in Chinese Han 156 ). In the study of common variant associations with lipid traits, several trends have become apparent. 129, 130, 135, 136, 157, 158 First, there was encouraging concordance among GWAS findings with respect to both established and many novel lipid-associated genes. Second, there was a somewhat discouragingbut familiar in the wider realm of GWAS of complex disease phenotypes-lack of cumulative clinical or diagnostic power in the genetic associations discovered via GWAS arrays, with only ≈10% of the total variation in lipid traits (≈25% of phenotypic variation attributable to genes) explained by GWASdiscovered associated genotypes.
129, 159 Clearly, as with many other CVD phenotypes, lipid phenotypes also demonstrated the problem of "missing heritability." It bears mentioning, however, that data from lipid GWASs proved pivotal in understanding missing heritability as a paradigmatic issue rather than a simple methodological problem. Finding significant associations between genes with products that play known roles in lipid metabolism was reassuring.
The rare variant paradigm has only begun to be explored in the realm of lipid genomics, and it remains unclear to what degree rare mutations might account for missing heritability in lipid traits. 160, 161 To date, whole-exome sequencing and whole-genome sequencing have been used to uncover genetic defects leading to mendelian lipid disorders such as a rare form of severe hypercholesterolemia, found through wholegenome sequencing, 162 and rare variants in ANGPTL3 causing a form of familial combined hypolipidemia, found with whole-exome analysis. 163 Currently, analytical strategies are being devised and tested to adapt cost-feasible, whole-exome sequencing to discover causal and risk variants for nonmendelian, complex diseases and health-related traits, including lipid phenotypes. Hope remains high that these approaches will yield findings of clinical relevance.
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Diabetes Mellitus
Type 2 diabetes mellitus (T2DM) is characterized by impaired pancreatic β-cell response and insulin resistance, and T2DM has deleterious effects on cardiovascular risk and accounts for considerable morbidity and mortality. 165, 166 The prevalence of diabetes mellitus is on the rise, highlighting the need for intense scientific interest to elucidate the genetic origins of this disease. Before the sequencing of the human genome 167 and the subsequent completion of the human haplotype mapping (HapMap) project, 168 genetic studies of T2DM and diabetes-related traits focused on linkage peaks from family studies and biological candidate genes. However, consistent associations with T2DM were found for only a few genes such as TCFL7, PPARG, and KCNJ11. [169] [170] [171] [172] The breakthrough initial GWASs of T2DM successfully identified TCF7L2, PPARG, and KCNJ11 and >10 novel loci modifying T2DM risk. [173] [174] [175] [176] [177] The formation of diabetes genetics consortia like the Diabetes and Genetics Replication and Meta-Analysis Consortium has increased the sample sizes and thus statistical power for association analysis, and meta-analyses with large-scale replication have identified ≈65 loci modifying T2DM risk (summarized in Table 5 ). [177] [178] [179] As with other CVD risk factors, the T2DM genetic variants identified through GWASs and other mechanisms have modest effect sizes, explaining ≈10% of the disease heritability in individuals of European ancestry. 179 In non-European populations, novel T2DM loci have been identified, including KCNQ1 in East Asian populations 190, 191 and other novel associations reported in populations of Asian ancestry. 186, 187, 189 Parallel to the effort to uncover T2DM susceptibility loci, the Meta-Analyses of Glucose and Insulin-Related Traits Consortium was formed to investigate the genetic variability between loci influencing changes in the levels of glycemic traits (eg, fasting glucose and insulin) in people without diabetes mellitus. This consortium identified variants in MTNR1B, a known circadian regulation gene, associated with increased levels of fasting glucose. This locus has also been shown to contribute to T2DM susceptibility. 192 Further meta-analyses for quantitative metabolic traits, including recent large-scale replication efforts with the Metabochip, have identified 36 loci for fasting glucose, 19 loci for fasting insulin, and 9 loci for 2-hour glucose. Of these, 22 loci for fasting glucose, 13 loci for fasting insulin, and 8 loci for 2-hour glucose showed at least a nominal association with T2DM (P<0.05; false discovery rate, q<0.05). 181 Of note, not all fasting glucose loci are also associated with T2DM, suggesting that the mechanism by which glucose is elevated may be essential in the development of T2DM. 181, 193 Many of the initial T2DM susceptibility genes were related to β-cell mass or function rather than insulin resistance, and few loci for fasting insulin, or the homeostasis model assessment-estimated insulin resistance index, have been uncovered (including IRS1 and IGF1). 194, 195 Whether these findings reflect a more complex genetic architecture of insulin resistance versus a more important role of β-cell dysfunction in T2DM remains to be determined. In this context, it is interesting to note that genes in the adipocytokine pathway implicated in insulin resistance showed the strongest enrichment of genetic association with T2DM among 16 gene sets tested by the Diabetes and Genetics Replication and MetaAnalysis Consortium using gene set enrichment analysis. 178 Furthermore, the fraction of fasting insulin loci also nominally associated with T2DM (68.4%) is higher than that of fasting glucose loci (61.1%). 181 The next steps needed to deepen our understanding of the genetics of T2DM and related traits include identification of the causal variants and integration of existing and future large-scale meta-analyses with other data sources (eg, sequencing, expression, and metabolomics data). December 24/31, 2013 family studies support the heritability of inflammatory biomarkers. 199, 200 The majority of recent studies examining the genetic contribution to inflammatory marker concentrations have focused on CRP levels (as summarized in Table 6 ). In 2008, a genome-wide analysis conducted in the Women's Genome Health Study identified 7 loci associated with plasma CRP levels, including APOE, LEPR, HNF1A, IL6R, and GCKR. 203 The putative functions of these loci suggested that CRP-affecting variants are also related to insulin resistance, the metabolic syndrome, β-cell function, weight gain, and premature atherosclerosis. The most recent meta-analysis of GWASs for CRP levels, including >80 000 subjects, confirmed the 7 previously identified loci and found 11 new loci. 201 Together, these loci are implicated in pathways related to the metabolic syndrome (HNF1A and PTPN) and immune response (NLRP3, IL1F10 and IRF1), and several were in regions previously not known to play a role in inflammation. A GWAS in ≈13 000 Japanese subjects also has identified variants in IL6 as being significantly associated with serum CRP levels. 205 It is estimated that the genetic risk loci for CRP explain ≈5% to 10% of the variation in CRP levels. 201, 203 Despite being strongly associated with CRP levels (variants in the CRP gene are associated with up to 30% per allele difference in concentration of CRP), 201, 204, 206, 208 variants in the CRP locus have not been found to be associated with CAD risk. 206, 208 Likewise, a combined genetic risk score of the 18 CRP-related loci showed no consistent associations with MI or CAD risk. 201 These studies suggest that CRP concentration itself is not a causal factor in CAD.
Recent studies of the genetic determinants of other inflammatory markers have extended prior linkage and candidate gene work. Like CRP, plasma fibrinogen levels are associated with increased risk of CVD, 209, 210 but the 3 genes encoding the fibrinogen protein account for only a fraction of the variance of circulating levels of fibrinogen. 211 Two GWASs have identified several new loci for fibrinogen, 212, 213 IRF1, IL6R, and NLRP3, which have also been found in relation to CRP levels; PCCB; CSPI; and the 17q25.1 locus (intronic to CD300LF and RAB37). Results of GWASs confirmed the associations of variants in intercellular adhesion molecule-1 (ICAM-1) and soluble P-selectin genes and found an association of soluble intercellular adhesion molecule-1 and P-selectin levels with 214, 215 Variants in the MTHFR, CBS, MTR, and MTRR genes are known to influence homocysteine concentrations, although recent controversies have arisen about the influence of moderate homocysteine elevation on CAD. 216 Recently, SNPs in and adjacent to ZNF366, PTPRD, DPEP1, and CPS1 have also been identified as novel determinants of plasma homocysteine. The relationship of these variants to CVD has yet to be systematically evaluated.
Pharmacogenetics
Genetics of Adverse Drug Reactions
The study of severe adverse drug reactions has yielded some of the most impressive and useful pharmacogenetic advances to date. What used to be regarded as idiosyncratic, unpredictable type B reactions, for instance, abacavir and the hypersensitivity syndrome, 217, 218 flucloxacillin and drug-induced liver injury, 219, 220 and statin-associated myopathy, 221, 222 are now known to be strongly associated with specific genetic variants. At this stage, we now have randomized trial evidence that screening prevents hypersensitivity reactions to abacavir. 223 Because of the large effect of study size for these drug-gene interactions, GWASs of severe adverse drug reactions have typically included 50 to 200 cases 217, 219, 220, 222 rather than the tens or hundreds of thousands of subjects typically included in GWASs of phenotypes such as lipids and BP. 92, 129 Lumiracoxib, a cyclooxygenase-2 inhibitor, for example, was never approved because of drug-induced liver injury. 220 A GWAS of 41 cases and 176 controls identified a high-signal marker, a finding that was replicated in another 98 cases and 405 controls. Fine mapping identified a strong association with an HLA haplotype (allelic odds ratio, 5.0; 95% confidence interval, 3.6-7.0). The identification of such genetic risk factors offers the possibility of improving the safety profile of prescribed drugs. However, even odds ratios as high as 5 do not function well as predictive tests. 224 Withholding the drug from the 20% to 30% of the controls who carried the risk allele would reduce the occurrence of elevated liver function tests from 2.5% to ≈1%.
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Advances
Pharmacogenetics of Clopidogrel
In the area of CVD, clopidogrel is perhaps the best example of recent progress. Clopidogrel, an antiplatelet agent, is administered as a prodrug that requires a 2-step enzymatic activation, for which cytochrome P450 2C19 (CYP2C19) is a key enzyme. 225, 226 Numerous loss-of-function genetic polymorphisms in CYP2C19 lead to reduced generation of the active metabolite of clopidogrel, along with reduced antiplatelet effects. The most common of these loss-of-function alleles is called *2, and ≈25% to 30% of those of European and African ancestry and up to 70% of those with Asian ancestry carry at least 1 loss-of-function allele. 225 On the basis of the published and internal literature at the time, the US Food and Drug Administration issued a boxed warning on the clopidogrel (Plavix) product label in March 2010, informing clinicians of the potential for reduced efficacy of clopidogrel based on the CYP2C19 genotype; The boxed warning does not mandate genetic testing but provides information on risk associated with certain genotypes and general suggestions for alternative approaches. In response to the boxed warning, the American Heart Association and American College of Cardiology Foundation issued a clinical alert to provide guidance to clinicians about the boxed warning. 227 The recommendations in this clinical alert focused on continued adherence to current guidelines for the use of antiplatelet therapy. As a result of the lack of controlled trial data on the predictive value of pharmacogenetic testing, they could not recommend routine genetic (or platelet function) testing. They did, however, conclude that clinicians must be aware of the influence of CYP2C19 genotype on clopidogrel metabolism and antiplatelet activity, along with the potential for worse outcomes based on the CYP2C19 genotype.
However, studies published since that time and several different meta-analyses have created controversy about the role of CYP2C19 genotype and outcomes with clopidogrel therapy (Table 7) . A meta-analysis by Mega and colleagues 228 found that the presence of 1 or 2 loss-of-function alleles was associated with an increased risk of events in patients who were aggressively managed (most with percutaneous coronary intervention and stents). The meta-analysis by Bauer et al 229 was restricted to patients with CAD but included indications for clopidogrel when the benefit over placebo is lower than in post-percutaneous coronary intervention patients. Except for 
Interpretation of the clopidogrel pharmacogenetics studies and meta-analyses has been varied. Some point to the metaanalyses by Bauer et al 229 and Holmes et al 230 to conclude that there is not a clinically relevant effect of CYP2C19 genotype on treatment-related outcomes with clopidogrel. For example, in the Holmes et al article, for analyses that stratified the studies by the number of outcomes, the association tended to be null in the large studies, and the evidence for small-study bias was pronounced (P=3.2×10 −7 ). All these meta-analyses [228] [229] [230] relied largely on observational analyses in treated patients with or without genetic variants. In a formal test for effect modification in 4 placebo-controlled trials, 230 there was weak evidence for an interaction with bleeding outcomes (P=0.07) but little or no evidence for any association with cardiovascular events (P=0.37). 228, 231 Thus, small-study bias and random variation may explain the observational findings to date.
An alternative interpretation is that the magnitude of benefit of clopidogrel in a given patient population influences the risk associated with CYP2C19 loss-of-function variants. 232 Specifically, if the magnitude of benefit is small, the impact of genotype on clopidogrel efficacy may also be small. Therefore, the risk of genotype appears to be greatest among patients for whom clopidogrel has the greatest efficacy (ie, largest risk reduction), specifically those undergoing percutaneous coronary intervention with stenting. Meta-analyses suggest that this group may be at up to 3-to 4-fold increased risk for stent thrombosis among *2 variant carriers. 228, 231 Additionally, the Mega et al 228 meta-analysis focused primarily on this population and observed significant risk for other cardiovascular outcomes. In contrast, studies of lower-risk patients (eg, those with CAD without percutaneous coronary intervention, atrial fibrillation) do not suggest an important influence of the CYP2C19 genotype on treatment-related outcomes with clopidogrel. This interpretation assumes a higherorder interaction, one among drug, gene, and magnitude of drug benefit/indication and outcome.
The new antiplatelet agents prasugrel and ticagrelor are not influenced by CYP2C19 genotype 233, 234 and may represent a therapeutic alternative. Guidelines have been written that provide recommendations on use of CYP2C19 genotype data in clopidogrel-treated patients when the genetic data are available.
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Pharmacogenetics of Warfarin
Used as an anticoagulant in patients with venous thromboembolism or atrial fibrillation, warfarin has a narrow therapeutic index with the result that relatively small levels of underdosing or overdosing are associated with increased risks of clotting or bleeding. Candidate gene studies identified and GWASs confirmed the importance of the CYP2C9 and VKORC1 variants in the dosing of warfarin and potentially its hemorrhagic complications. [236] [237] [238] [239] The US Food and Drug Administration has made 2 revisions to the warfarin product label to incorporate information on the influence of CYP2C9 and VKORC1 genotypes on warfarin dose requirement, the most recent of which included a table with dosing recommendations by genotype. Dosing algorithms have also been developed that incorporate genetic and clinical information to allow initial dose prediction, and data suggest the ability to more closely approximate a stable warfarin dose requirement through this pharmacogenetic approach than through a clinical algorithm, the US Food and Drug Administration dosing table, or standard dose initiation. [240] [241] [242] Whether genotype-guided warfarin dosing improves health outcomes in clinical care is a question of major debate. In 1 recent study, investigators compared 504 patients whose warfarin therapy was managed via a warfarin pharmacogenetic algorithm and 1866 parallel control subjects. 243 The patients on the pharmacogenetic-adjusted dose participated in a randomized trial that compared 2 algorithms, which did not differ. The control subjects were an observational cohort of patients who did not enroll in the clinical trial and who differed on many risk factors from the pharmacogenetics-adjusted-dose trial participants. A variety of improvements were observed in the pharmacogenetic algorithm group, including significantly fewer out-of-range international normalized ratios at 30 days and 30 months, a greater percentage of time within the target international normalized ratio, and fewer serious adverse events. Although studies of this type of design have certain limitations, this study suggests the potential benefit of pharmacogenetic-guided warfarin dosing. Several ongoing large, randomized, controlled trials will help further define the clinical relevance of warfarin pharmacogenetics testing; the first of these is expected to be published in late 2013. 
Drug-Gene Interactions Predicting Efficacy
In 1 candidate gene study, a genetic variant in the HMG-CoA reductase gene, present in 6.7% of patients, modified the LDL-C response to pravastatin by 6.4 mg/dL. 244 In a GWAS, a variant in the ataxia telangiectasia mutated (ATM) gene was associated with a 0.11 percentage per allele decrease in glycated hemoglobin in response to starting metformin. [245] [246] [247] However, these effect sizes are small and difficult to distinguish from random variation in individual patients. Indeed, the metformin finding is less important for its potential clinical applications than for the biological insight provided by this link between glucose control and a gene involved in the response to DNA damage.
245,246
Guidelines for Genetic Testing
The Evaluation of Genomic Application in Practice and Prevention Working Group 248, 249 has developed guidelines that use criteria similar to those used by the US Preventive Services Task Force. The key criteria include analytic validity, clinical validity, and clinical utility. For several drugs, including clopidogrel and warfarin, the studies to date have provided evidence of analytic and clinical validity for selected outcomes. Ongoing trials are needed to determine whether the use of genetic tests in patients for whom clopidogrel and warfarin are indicated improves care, reduces adverse events, or reduces costs. A demonstrated need for genetic testing in these patients may simply serve as an incentive to use other drugs that have the same indication and have a similar risk-benefit profile without any requirement for genetic testing.
Mendelian/Rare Variant Disease and the Contribution of Exome Sequencing
Mendelian disease has been most commonly understood to be that which can be explained principally by 1 disease locus (usually 1 rare variant, also commonly called a mutation) and, when familial, exhibits patterns of mendelian inheritance (autosomal, X-linked, dominant, recessive, mitochondrial). Mendelian diseases may occur as syndromic or nonsyndromic, in which a syndrome is a recurring pattern of abnormalities characteristic of a specific disorder or disease. Historically, variants within genes causing mendelian disease were discovered through parametric linkage analyses of large multiplex families. Because very large extended families with multiple affected family members continue to be very infrequent and because mendelian disease often results from genetic variation within coding sequence, exome sequencing has recently provided a new and powerful approach to identify disease genes in smaller kindreds 250 or even unrelated individuals with a similar phenotype not amenable to linkage analysis. 251, 252 Although analyses of the impact of rare variants for complex disease are ongoing 3, 5, 13, 253, 254 for a variety of cardiovascular and vascular phenotypes, these approaches and data have also had an impact on the discovery for diseases designated historically as mendelian such as the cardiomyopathies, [255] [256] [257] inherited arrhythmias, 258 aortic aneurysm, 73 and congenital heart disease (CHD). 259 Because of the dramatic degree that each individual harbors rare variants, several dozen of which are unique and potentially injurious, 13,260-262 even family-based exome studies of classic mendelian traits using sophisticated filtering approaches 11, 263 have found it difficult to identify only 1 causative mutation because multiple plausible disease-causing variants may be identified. 11, 255, 259, 261, 262 Previous work has suggested that the majority of rare missense alleles may be damaging. 264 Although the canonical mendelian genetic disease paradigm suggests that the condition under study results from 1 rare, highly pathogenic variant, this paradigm, particularly for diseases considered mendelian but with marked locus and allelic heterogeneity (such as dilated cardiomyopathy [DCM] , as noted below), will undoubtedly reveal additional complexity as exome sequencing continues in much larger, well-phenotyped cohorts. Almost all mendelian diseases, particularly those adult-onset conditions common in CVD (Table 8) , show variable phenotypes from reduced penetrance and variable expressivity, age of onset, and severity of disease, even with the same mutation in closely related family members. Such variable expressivity implies the presence of other modifying factors. These factors may be genetic, environmental, epigenetic, or a combination. How much rare or common genetic variation beyond that of "1 causative mutation" influences mendelian disease is uncertain, and the full impact of all rare variant variation for mendelian disease remains to be fully elucidated. 5 Furthermore, where the boundaries of a classic, 1-locus (1 mutation) mendelian disease meet common, complex disease genetics is also a pertinent question for the field. 3, 5, 11, 315, 316 We also note that the prevailing concept that most mendelian diseases are "rare" needs reevaluation. Although the causative or primary variant driving the pathological cardiovascular phenotype of interest may in itself be very rare or even private, and even if the gene harboring such a variant may contribute only a small fraction to the overall disease burden of that phenotype, the collective impact of all such variants in the several or many genes related to a phenotype may have a greater population impact than previously understood. Preliminary studies 256, 258 raise this issue, and the rapid pace of progress, particularly that driven by exome sequencing in very large, well-phenotyped cohorts for diseases traditionally viewed as mendelian, will bring greater clarity to this issue.
On the basis of the recent explosion of next generation sequencing data and the impact of rare variants on mendelian CVD, we include a brief update on the cardiomyopathies (hypertrophic cardiomyopathy [HCM], DCM, arrhythmogenic right ventricular cardiomyopathy [ARVC], restrictive cardiomyopathy, and left ventricular noncompaction cardiomyopathy) and the heritable arrhythmias, specifically the long-QT syndrome, catecholaminergic polymorphic ventricular tachycardia, the Brugada syndrome, and related diseases (Table 8 ). Significant progress has also been made recently with other mendelian disease, including aortic aneurysm and syndromic and nonsyndromic CHD (Table 8) .
Cardiomyopathies
The cardiomyopathies are defined as diseases principally affecting the myocardium. Familial cardiomyopathies of any category are considered to have a genetic basis because their heritable nature implies a genetic cause (Table 8) , although other possible environmental or more complex genetic influences, as December 24/31, 2013 noted above, have not yet been delineated. Furthermore, the degree that sporadic, nonfamilial disease has a genetic basis is less well understood, especially for DCM. Some aspects of cardiomyopathy genetics are similar in that the majority of known disease is caused by rare, nonsynonymous missense variants with occasional nonsense, short insertion/deletion 316 for a summary of clinical diagnostic molecular genetics categories). Copy number variants (deletions, insertions, duplications, or transversions of large pieces of DNA, from <1 kilobase to several megabases) are also plausible causes of cardiomyopathy, but their impact remains largely unknown because few systematic copy number variant studies have been completed. For almost all cardiomyopathy rare variants, marked allelic heterogeneity is the rule (many different mutations in a gene), with most identified mutations occurring only in the family under investigation (a private mutation). Only a few rare variants have been observed in multiple unrelated probands. Although all cardiomyopathy phenotypes have been shown to result from rare variants in >1 gene (locus heterogeneity), the degree of locus heterogeneity varies greatly and contributes to the complexity of each phenotype (Table 8 ).
Hypertrophic Cardiomyopathy
HCM was the first cardiomyopathy with a specific genetic diagnosis (see the articles by Bos et al 317 and Maron et al 318 for reviews focused on HCM genetics). Since 1990, hundreds of rare variants have been identified with >80% of known genetic cause occurring in 2 genes (MYH7, MYBPC3) and ≈95% when 3 other genes are included, all of which encode contractile proteins (Table 8) . Thus, HCM is considered a genetic disease of contractile proteins. Left ventricular hypertrophy resembling HCM as a consequence of infiltrative or syndromic disease must be differentiated from that caused by HCM mutations. 319 These disorders include Fabry disease, Danon disease, and mitochondrial or other syndromic disease (see the article by Hershberger et al 265 for common syndromic HCM). Next-generation sequencing-based panels of genes (testing 10-20 or more genes) are now available for clinical use, making family-based molecular genetic evaluation and diagnosis 265, 266 easily attainable for HCM.
Dilated Cardiomyopathy
Family-based clinical studies have shown that 20% to 50% of patients diagnosed with DCM of unknown cause can be identified as having familial DCM after clinical screening of family members. 320 The causal pathway for DCM can be activated but asymptomatic for years, 321 providing the opportunity for early clinical or biomarker-aided diagnosis. 321, 322 Approximately 40% to 50% of genetic cause has been identified in familial DCM, with truncating variants in the giant protein titin, encoded by TTN, accounting for 18% to 25% of cases 270 and rare variants in >30 genes also implicated in the DCM cause. 323 Unlike HCM or ARVC, which are genetic diseases of the sarcomere or desmosome, respectively, DCM gene ontology 316 includes a number of different protein cascades that, when perturbed, will result in DCM. DCM genes involved include those encoding proteins of the sarcomere, z disk, cytoskeleton, nuclear membrane, RNA binding, ion channels, sarcoplasmic reticulum, transcription factors, γ-secretase, mitochondria, and others. 316 Collectively, this indicates that DCM is a final phenotype that may result from a variety of diverse injury pathways 316, 321 and that identifying the remaining genetic cause of DCM will lead to greater insight into DCM pathogenesis. 316 Unlike HCM, ARVC, restrictive cardiomyopathy, and left ventricular noncompaction cardiomyopathy, DCM has not been classified as a genetic cardiomyopathy but rather of mixed phenotypes with some genetic origin. 324 Although a consensus has emerged that familial DCM has a genetic basis and some preliminary data suggest that some sporadic disease also has a genetic basis, 271 the degree to which sporadic idiopathic DCM (DCM of unknown cause in the absence of familial disease) has a genetic basis remains unknown. 316 This remains a key question because of the prevalence of idiopathic DCM in the population and its impact as a major cause of systolic heart failure.
Arrhythmogenic Right Ventricular Cardiomyopathy
A great deal of progress has been made in understanding ARVC genetics, 266, [274] [275] [276] [277] with evidence indicating that ARVC is a genetic disease of the desmosome (Table 8) .
Restrictive Cardiomyopathy
Restrictive cardiomyopathy, also classified as a genetic cardiomyopathy, 324 occasionally can be observed segregating in families and has been shown to result from mutations in contractile proteins (Table 8) . 265, [293] [294] [295] Most genetic cause remains unknown.
Noncompaction Cardiomyopathy
Noncompaction cardiomyopathy, recently formally defined as a genetic cardiomyopathy, 318 has evolved as an echocardiographically based diagnosis 318, [325] [326] [327] of the ratio of noncompacted to compacted myocardium. It has been associated with rare variant genetic cause (≈29%), most commonly within sarcomeric genes [296] [297] [298] (Table 8) .
Heritable Arrhythmias
These disorders result principally from rare variants in coding portions of key ion channels; similar to HCM, most known genetic causes for these syndromes occur within genes encoding ion channels (Table 8 ). Because of their relatively high sensitivity for clinical molecular genetic testing and the relatively modest number of genes that need to be evaluated, clinical molecular genetic testing for these genes has become widely available with rapid clinical uptake.
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Thoracic Aortic Aneurysm and Dissection
Thoracic aortic aneurysms and other aortic pathology such as dissection and rupture are an important cause of cardiovascular morbidity and mortality. Familial forms of aortic diseases are attributable to a number of known rare variant mutations in extracellular matrix proteins such as collagen 3A1 (COL3A1) in vascular-type Ehlers-Danlos syndrome (type IV) 328 and fibrillin (FBN) in Marfan syndrome, as well as genes involved in smooth muscle cell structure and function such as ACTA2 mutations in an autosomal-dominant inherited thoracic aortic aneurysm, 75, 78, 328 variants in the smooth muscle myosin gene (MYH11), and variants in multiple transforming growth factor-β signaling genes, including TGFBR1, TGFBR2, TGFB2, and SMAD3 (Table 8) . [61] [62] [63] [64] [65] [66] 68, [71] [72] [73] [74] 308 Genetic forms of thoracic aortic aneurysms are also known in conditions such as bicuspid aortic valve, although the causal December 24/31, 2013 gene is not known for most cases. 329 In the context of bicuspid aortic valve, screening of first-degree family members is recommended by echocardiography to define the structure of the aortic valve and aortic root measurement in case a bicuspid aortic valve is detected. 330 An important lesson from the genetic analyses of connective tissue diseases is that although the extracellular matrix composition is altered in these disorders, leading to potential defects in tensile strength of the aortic wall, the primary molecular defect may be regulation of inflammatory pathways and arterial homeostasis. For example, in Marfan syndrome, fibrillin mutations lead to dysregulation of transforming growth factor-β in the arterial wall. 331 Further confirming the importance of the transforming growth factor-β pathway in aortic aneurysm is the finding that mutations in other genes in the transforming growth factor-β pathway also cause aortic pathology. However, the distribution of phenotypic effects in syndromes such as the Loeys-Dietz syndrome is distinct from that seen in Marfan, with a higher propensity for arterial tortuosity and dissection or rupture in the absence of aneurysm. 64 The full distribution of allelic effects has yet to be defined for the known genes for these disorders, and a number of familial syndromes such as bicuspid aortic valve require further investigation to identify the causal mutation(s) and possible therapeutic targets. In contrast to the aneurysmal diseases outlined above, elastin (ELN) mutations cause supravalvular aortic stenosis.
332
Congenital Heart Disease
Only a handful of single-gene or single-locus disorders have been identified in patients with CHD to date (reviewed by Pierpont et al 309 ). Although such disorders currently account for only a minority of CHD cases, they have nonetheless increased our understanding of the genes and developmental pathways associated with CHD. These findings highlight the heterogeneity of CHD and underscore the work yet to be done because most sporadic cases are likely caused by a combination of rare, and possibly common, variants in >1 locus.
The minority of congenital heart defects display patterns of mendelian inheritance and can be explained on the basis of rare variants in a single locus. CHD often occurs within the context of syndromes, and molecular analysis of familial syndromic disorders has identified several disease-causing genes such as TBX5 for Holt-Oram syndrome or JAG1 in Alagille syndrome (Table 8) . 313, 333 Large families with the Holt-Oram phenotype permitted parametric linkage analyses and the subsequent identification of a disease gene, TBX5; 334 Visible chromosomal changes on a karyotype in a subset of cases with Alagille syndrome pointed to a disease locus on chromosome 20p12, 335 and subsequent positional cloning and sequencing efforts identified mutations in JAG1, a ligand in the Notch signaling pathway. 310, 311 Originally defined by interlobular bile duct paucity, CHD, vertebral and ocular anomalies, and dysmorphic features, Alagille syndrome characterized by JAG1 mutations is now recognized to display marked phenotypic variability. X-linked inheritance observed in rare families with heterotaxy syndrome led to the discovery of rare, diseasecausing variants in the transcription factor ZIC3. [336] [337] [338] Although each disorder is considered to be a mendelian or rare variant disorder, more complex factors likely modify the expressivity of any single rare variant in all 3 disorders. Other examples of rare variant syndromes with CHD include the genetically heterogeneous Noonan syndrome 309, 339 and deletion syndromes such as 22q11.2 deletion syndrome 309,340 and Williams syndrome. 341 More recently, rare variants in single genes have been implicated in a small subset of nonsyndromic CHD. Mutations of the key transcription factor NKX2.5 have been identified in cases with atrial septal defects and concurrent atrioventricular conduction delay. 312 Similarly, mutations in the transcription factor GATA4 have been identified in nonsyndromic cases with atrial and ventricular septal defects. 313 Most recently, NOTCH1 mutations were found in 2 kindreds and occasional sporadic cases with aortic valve disease. 314 Rare variants have been identified in numerous candidate cardiac genes (Table 8) , although none account for a substantial amount of disease burden in the general population.
Functional Translation of Genetic Findings for CVDs and Stroke
Translational Road Map
Translational cardiovascular medicine identifies and validates science-driven systems that effectively address patient and community needs. The translational continuum highlights the unifying framework that bridges fundamental discovery to human application, advancing acquired information into clinical practice, disseminating best practices into communities, and modifying the behavior of populations to improve wellness. Advances in functional genomics and translational biology provide the foundation to transform understanding of mechanisms that relate molecular events to health and disease, to enable early and accurate risk stratification and diagnosis of cardiovascular disorders, to develop personalized preventive and therapeutic regimens for CVDs, and to contribute to evidence available to guide the practice of cardiovascular medicine and improve public health. 342 Areas of priority include the determination of genetic variants associated with specific diseases; delineation of molecular mechanisms that account for genetic susceptibility or resistance to disease; mapping molecular signatures that allow complex disease phenotypes to be stratified into clinically relevant categories; and definition of molecular, cellular, and organ-specific responses to environmental exposures and the mechanisms by which heritable factors interact in disease initiation and progression and in therapeutic response. 343 Enabling platforms built on the "omics" revolution include systems biology and network medicine. Implementation of network systems biology principles offers unparalleled opportunity to synthesize and integrate inherently complex high-throughput data for meaningful interpretation. 344 These approaches allow the establishment of mechanistic relationships among numerous individual molecules that constitute larger systems of cells, tissues, and organs to generate predictive models of pathophysiological processes and to anticipate intervention outcomes. 345, 346 Emerging applications of systems biology range from modeling and targeting disease-corrupted networks to screening chemical or ligand libraries for the identification and validation of drug-target interactions for improved efficacy and safety. 347 Ultimately, advancing fundamental discovery from the bench to patients at the bedside will require integration across the translational continuum. 348, 349 Translation of discovery is best accomplished by interdisciplinary teams with synergistic areas of expertise. These teams comprise scientists, clinician investigators, practitioners, and genetic counselors, as well as experts in epidemiology, informatics, regulatory science, ethics, and health services research. The full spectrum of translation, from discovery to disease prevention, is best served by integrated approaches with bidirectionality in translational research and informed prioritization of medical research aligned with community needs. [348] [349] [350] Integration of genetics with bioinformatics approaches is vital for the development of patient-specific libraries that match varying molecular characteristics with disease traits. The growing understanding of genotype/phenotype relationships, enabled by high-throughput technologies, offers the opportunity to deploy patient-specific molecular panels. In this context, bioinformatics analysis maximizes integration of current knowledge with patient data to obtain a precise characterization of individual disease states, informing management algorithms. 351 Individual variability in disease manifestation and treatment outcomes poses a challenge to optimal patient management and measures to ensure population wellness. Individualized medicine intends to provide personalized solutions based on patient-specific mechanisms of disease. 350, 352 Molecular sciences, including functional genomics and translational biology, have catalyzed the development of more precise diagnostic and therapeutic platforms tailored to the individual patient profile. Patient-centric algorithms, grounded in the individual's genetic makeup, are emerging tools in contemporary cardiovascular medicine. 353, 354 Examples include the evolution of pharmacogenomics paradigms 355, 356 and the emergence of individualized platforms for refined therapeutics and diagnostics applications. 357, 358 Case in point, the discovery of genetic variation resulting in pharmacokinetic effects is showcased with the impact of the polymorphisms in CYP2C19 that identify patients at higher risk for adverse events such as death, MI, stroke, and coronary stent thrombosis, a highrisk group that should be targeted with alternative antiplatelet medications. 355 Another emerging platform is that of personalized regenerative theranostics, offering a unique approach to expose mechanisms of disease origin in the context of dysfunctional cell biology. Indeed, the breakthrough technology of nuclear reprogramming enables the resolution of molecular dynamics that define and regulate individual regenerative capacity, paving the way for next-generation, patient-specific diagnostic and therapeutic applications. 357 Implementation of personalized practices offers unprecedented opportunities for earlier diagnosis and targeted disease prevention, zooming in on the root cause of the underlying defect.
Discovery Interpretation and Hypothesis Generation
Although understanding the functional consequence of genetic discoveries through mechanistic experiments remains the cornerstone of successful translation, we note several examples of recent population genetic studies that have shed light on the pathophysiology and genetic architecture of traits related to CVD. 359 Examples in this context include the pleiotropic vascular effects associated with variants at the 9p21 susceptibility locus for CAD, the profile of novel T2DM variants, and results of large-scale mendelian randomization related to CVD.
The 9p21 Susceptibility Locus and Insights into the Role of the Vessel Wall in CVD
The chromosome 9p21 susceptibility locus for CAD was among the earliest discoveries made in CVD genetics through GWASs. [24] [25] [26] As stated earlier, it also became clear that the exact same variants at chromosome 9p21 were associated with a variety of other atherosclerosis-related traits, including coronary artery calcification, peripheral artery disease, and angiographic CAD, as well as arterial wall aneurysms in either the presence or absence of atherosclerosis (abdominal aortic and intracranial berry aneurysms).
27, [360] [361] [362] The variants identified led to excessive cellular proliferation in a murine model and in vitro. 35 The pattern of pleiotropic associations suggests a hypothesis that cells responsible for maintaining the integrity of the arterial wall may mediate both atherosclerotic and nonatherosclerotic diseases. 363, 364 Although this hypothesis is the leading hypothesis tying these observations at the population level together, it remains to be proven.
Genetic Architecture of T2DM
T2DM has been traditionally viewed as a disease of longstanding peripheral insulin resistance, which eventually overrides the compensatory ability of pancreatic β cells to maintain euglycemia through increased insulin secretion. [365] [366] [367] Curiously, a large fraction of the initial susceptibility loci for T2DM uncovered to date through GWASs track with indexes of β-cell function rather than indexes of insulin sensitivity despite prior evidence that both traits are heritable to a substantial degree. 180, 195, 368, 369 Assuming that both β-cell dysfunction and insulin resistance are equally important in the pathogenesis of T2DM, these findings suggest a genetic architecture for insulin resistance that is considerably more complex than that of insulin secretion.
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Use of Mendelian Randomization for Improving Causal Inference of CVD Risk Factors
Observational epidemiologic studies not uncommonly identify modifiable risk factors that are strongly associated with CAD but are subsequently proven to be noncausal in nature through randomized, controlled trials. Notable recent examples include trials showing no association between CAD and various vitamin supplements (beta carotene, vitamin C, vitamin E), as well as hormonal replacement therapy. In addition, interventions that modify the levels of a purported risk factor are not always available for testing in a randomized, clinical trial (eg CRP). Recent GWASs have offered an alternative to such interventions by identifying ≥1 variants that are strongly associated with clinically meaningful differences in the levels of these risk factors. With the use of the principle of mendelian randomization, these crucial variants have subsequently served as instrumental variables to estimate the causal effects of the risk factors they track. 370, 371 Recent large-scale mendelian randomization studies persuasively conclude that LDL-C, lipoprotein(a), and triglyceride-rich chylomicrons are causally associated with CVD, December 24/31, 2013 whereas the associations with high-density lipoprotein cholesterol, high-sensitivity CRP, and fibrinogen do not appear causal. 206, 208, [372] [373] [374] [375] [376] Although controversy exists on the precise mechanisms underpinning these findings, GWASs have been informative with regard to these questions.
Functional Analyses of GWAS Loci and Potential Translation of GWAS Findings
GWASs have been quite successful in identifying loci for a large number of traits and conditions, but for the vast majority of loci, the mechanistic links between the susceptibility loci and disease pathogenesis have remained elusive in the arena of CVD. In a number of recent studies, the causative genes have been identified for 2 GWAS loci for lipoprotein metabolism.
The Global Lipids Genetics Consortium GWAS identified multiple novel loci associated with lipoprotein metabolism, including a locus on chromosome 1p13. 129 The SNPs at this locus are associated with significant alterations in plasma LDL-C, 25 and variants at the same locus have been reported to be associated with risk of MI and CAD in independent GWASs. 19, 25, 129 In a recent functional analysis, 1 SNP at the 1p13 locus, rs12740374, was demonstrated to upregulate the transcription the SORT1 gene in hepatocytes by creating a binding site for the C/EBP transcription factor. 37 In a murine model, variable modulation of SORT1 expression resulted in altered hepatic very-low-density lipoprotein cholesterol secretion, which in turn altered plasma LDL-C and very-low-density lipoprotein cholesterol levels. Specifically, upregulation of SORT1 reduced plasma LDL-C concentration. These observations are consistent with human studies in which the minor allele, which is associated with overexpression of SORT1, was associated with reduced LDL-C levels.
Another locus associated with plasma lipid levels was mapped to chromosome 8q24. 129 The SNPs at this locus were associated with lower levels of serum high-density lipoprotein cholesterol, LDL-C, and triglycerides. The sole candidate gene at this locus, TRIB1, demonstrated higher hepatic expression in humans. Subsequently, the overexpression and knockout of the TRIB1 gene on plasma lipids were investigated in a mouse model. Hepatic overexpression of TRIB1 resulted in a reduction in very-low-density lipoprotein cholesterol and triglycerides; knockout of the gene had the opposite effect. Furthermore, rescue of the knockout phenotype was demonstrated with adenovirus 8-mediated gene delivery. 
Potential for GWAS Findings to Translate to Safe and Effective Therapies for CVD
With few exceptions, the effect sizes of common susceptibility variants in or near genes uncovered through GWASs have been modest in magnitude. 3, 378 Some have questioned whether such modest effects can ever be translated to therapies with major beneficial effects on outcomes. These concerns overlook the possibility that less common yet undiscovered variants in the same gene or deliberate targeting of gene activity through molecular or pharmacological means may demonstrate more powerful effects on clinical outcomes than the index variants. Evidence to support this possibility empirically already exists through the discovery that intronic variants in HMGCR, the target gene for statins, are associated with small changes in LDL-C. 134 Thus, GWASs coincidentally point to an existing therapeutic intervention that has been shown to consistently reduce CVD morbidity and mortality by an impressive 25% to 30%. 379, 380 Given this observation, it is hoped that at least some of the many other novel loci identified by GWASs with a functional significance that remains unclear possess potential for translation to safe and very effective therapies for CVD. 381, 382 As more susceptibility variants and genes are uncovered through further genome-wide discovery studies that incorporate both common and less common variants, new patterns of associations should emerge, and established associations should be clarified. To help determine and investigate these patterns, bioinformatics approaches to understand the roles of established pathways 383 and genetic pleiotropy 384 will be useful. These patterns will continue to provide the scientific community with the opportunity to generate well-informed hypotheses on the pathogenic mechanisms of CVD. It is hoped that these hypotheses will also maximize the efficiency of the basic science work that follows, shortening the time it takes to be able to apply these new discoveries in the clinical setting.
Counseling and Clinical Considerations
Attempts to improve CVD risk prediction through the incorporation of nongenetic biomarkers have been numerous over the past 10 to 20 years but have met with limited success when considering traditional metrics of model performance such as the C statistic. 385 In the face of this challenge, recent work has highlighted the limitations of the C statistic and introduced new model performance metrics that are clinically more relevant such as reclassification calibration, net reclassification index, and predictiveness curves. [386] [387] [388] [389] Although these studies have confirmed the ability of a multilocus genetic risk score derived from validated markers to identify people at higher risk of CVD, they have not yet convincingly demonstrated clinical utility. 38, 39 Thus, the routine genotyping of these genetic markers in the primary prevention of CVD cannot be recommended at the present time. The main obstacle to the successful incorporation of a CVD genetic risk score into clinical practice is the inability of current validated markers to explain a substantial proportion of the heritability of common forms of CVD. 3, 39, 353 As more risk variants are discovered over time, this situation is expected to improve. However, it is unclear when in the future we will surpass the threshold to make genetic risk prediction of common, complex forms of CVD clinically useful because this depends on several unknown factors, including the distribution of the effect sizes and frequencies of all CVDrelated variants not yet discovered. 3, 39, 353, 390 A vast majority of validated GWAS markers to date have been uncovered in European populations.
14 Substantial differences exist in the correlation patterns between variants in analogous genomic regions across major ethnic groups. 168 Thus, genetic risk scores derived from susceptibility variants identified in European populations may not perform as well in nonEuropean populations, particularly if they do not represent the actual causal variant in the region. 354, 391 This fact underscores the importance of conducting large-scale genomic studies in non-European populations going forward not only for gene discovery but also for developing optimal risk prediction algorithms for each of the major ethnic groups. The fundamental role of genetic counseling and testing remains unchanged for CVD in this update despite the numerous new genetic associations that have been established through GWASs. This recommendation should not be surprising given the limited clinical utility of discoveries to date. An initial and crucial step in assessing inherited risk of CVD is to carefully collect information on family history in addition to assessing for the presence and severity of traditional risk factors. An individual's family history can then be classified as low, medium, or high risk on the basis of the number and age of onset of affected relatives. 392, 393 In general, individuals with a high-risk CVD family history should be assessed for the need for medical genetics consultation. For many, the role of genetic testing is yet to be defined.
Genetic testing may be considered for index patients and their relatives who are suffering from a variety of familial cardiac conditions. Consideration of the complexity of the clinical presentation and suspected diagnoses is needed to decide whether specific gene testing is likely to be helpful. These diseases include heritable arrhythmias such as long-QT syndrome, catecholaminergic polymorphic ventricular tachycardia, Brugada syndrome, progressive cardiac conduction disease, short-QT syndrome, and cardiomyopathies such as HCM, ARVC, DCM, left ventricular noncompaction cardiomyopathy, restrictive cardiomyopathy, CHD, and others (Table 8) . For these disorders, consensus is emerging that the identification of either a new or a known mutation through genetic testing in a disease-associated gene in a family that is clearly at risk may have a major impact on the diagnosis, prognosis, and management of the condition. 266 Genetic testing may also augment clinical information obtained in mendelian inherited forms of early-onset CVD such as FH by improving adherence to treatment. 394 Genetic testing in the syndromic patient or familial cases with CHD may also have significant implications for reproductive counseling. As the number of children surviving to adulthood continues to increase, genetic testing and counseling will become increasing important in this population.
The role and impact of genetic counseling, provided by Master's trained and board-certified genetic counselors, are substantial and of key importance in providing skilled, insightful guidance for patients undergoing genetic evaluation. Of concern are the provision of adequate genetic counseling resources and the need for greater availability of genetic counseling as cardiovascular genomic medicine expands.
Integration of genomics into clinical medicine will require continuing education. The Inter-Society Coordinating Committee for Practitioner Education in Genomics, the International Society of Nurses in Genetics, the American Society of Human Genetics, and the National Genetics Education and Development Centre in the United Kingdom, as well as the former National Coalition for Health Professional Education in Genetics, promote the education of health professionals and provide access to human genetics and genomics information to improve health care. The National Human Genome Research Institute of the US National Institutes of Health recently identified 4 areas of education and training to actualize the benefits of genomics. 395 These include strengthening primary and secondary education and training science educators to foster future understanding of the probability and risk relevant to genomic medicine; conducting public outreach to provide education on the role of genomics in health and other areas; building healthcare providers' genomic competencies by integrating genomics into educational programs, licensing, and accrediting processes; and preparing and increasing the number of next-generation genomics researchers with expertise in both genomics and other disciplines beyond bioinformatics/computational biology and medicine. 395 All of these concerted educational efforts and goals will promote the successful integration of genomics into clinical practice and ultimately will improve health care.
The pace of human genetics discovery over the past 4 years has been nothing short of astonishing. However, the degree of genetic complexity of common diseases, including CVD, is now apparent and greater than we anticipated. 3, 359, 381 Thus, it seems likely that it will take several more years for us to demonstrate beyond doubt the predictive value of genetic testing in CVD. In the meantime, securing one's genetic profile is becoming increasingly easier because of major technological breakthroughs and the rise of direct-to-consumer genetic testing. 396 Indeed, the option of having one's entire genome sequenced to identify all of one's variants will likely arrive before the time when we will be able to make sense of all of the data generated. 397 The major challenge that follows is the appropriate interpretation, communication, and use of this data by trained health professionals in a manner that maximizes clinical utility for our patients while concurrently minimizing undue anxiety.
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Summary and Recommendations for Clinical and Public Health Practice and Further Research
The state of genomic knowledge of CVDs and stroke has expanded dramatically in recent years. Since our scientific statement was published in 2007, there has been rapid evolution of the genomic technologies, enabling a proliferation of GWASs investigating common, complex diseases, including CVDs and stroke. Because the number of associations that are tested within the GWAS platforms is large and most associations are weak, the process of conducting these studies has also evolved dramatically during this same period.
Researchers from around the world have come together as collaborators both to replicate (to reduce the potential for type I errors) and to meta-analyze data (to have statistical power to identify weak effects). We are on the precipice of further expansion to sequencing the whole genome of patients and large population cohorts to detect additional and rare variants predisposing to disease. Therefore, the next 5-year period will be consumed with mining the wealth of data that will be generated by this next phase of research. Additionally, progress in other "omics" fields will inform these sequence data to help in understanding function. Finally, the environment will be given more attention as we identify solutions to disease prevention and treatment.
We anticipate that in the near future we will determine genetically based disease susceptibility within individuals, families, and populations. We conclude this statement with recommendations intended to guide clinical and public health practice, to foster research, and to prepare both researchers and healthcare December 24/31, 2013 practitioners for the changes likely to occur as genetics are translated to the population and the clinical setting.
Currently Relevant Recommendations to Enable Future Discoveries and Optimization of Care
• Continue to develop and implement research that accelerates the translation of genomic discoveries to the prevention and treatment of CVDs and stroke. We suggest including the following:
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